N1A Stock Overview
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Navamedic ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.86 |
| 52 Week High | kr3.71 |
| 52 Week Low | kr2.68 |
| Beta | 0.28 |
| 1 Month Change | -5.30% |
| 3 Month Change | -12.00% |
| 1 Year Change | -7.74% |
| 3 Year Change | 13.49% |
| 5 Year Change | 80.67% |
| Change since IPO | 107.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| N1A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.4% | 3.2% | 1.7% |
| 1Y | -7.7% | -28.2% | 2.3% |
Return vs Industry: N1A exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: N1A underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| N1A volatility | |
|---|---|
| N1A Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: N1A has not had significant price volatility in the past 3 months.
Volatility Over Time: N1A's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 45 | Kathrine E. Andreassen | www.navamedic.com |
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet.
Navamedic ASA Fundamentals Summary
| N1A fundamental statistics | |
|---|---|
| Market cap | €50.71m |
| Earnings (TTM) | €324.41k |
| Revenue (TTM) | €43.55m |
156.3x
P/E Ratio1.2x
P/S RatioIs N1A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N1A income statement (TTM) | |
|---|---|
| Revenue | kr512.00m |
| Cost of Revenue | kr312.94m |
| Gross Profit | kr199.05m |
| Other Expenses | kr195.24m |
| Earnings | kr3.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.22 |
| Gross Margin | 38.88% |
| Net Profit Margin | 0.74% |
| Debt/Equity Ratio | 65.7% |
How did N1A perform over the long term?
See historical performance and comparison